AiCuris Anti-infective Cures AG, a leading company in the discovery and development of drugs against infectious diseases, and the biotechnology company Lysando AG with its Regensburg-based subsidiary Lysando GmbH, announced the expansion of their existing long-term collaboration for the development and optimization of Artilysin-based drug candidates for the topical treatment of infected, chronic wounds such as diabetic foot infections.
October 22, 2021
· 9 min read